Orion Corporation A【0M2N】銘柄情報

Orion Corporation A (0M2N) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

33.025

( - )

買値

32.20

売値

33.85

出来高

139

平均取引量 (3 か月)

198,636 €

財務取引量

0.00 日の範囲 0.00

33.025 52 週間の範囲 33.025

時価総額

4.652B

企業価値

10.264B

前日終値

33.025

始値

時刻

100

70.3

(O)

最終取引時間

VWAP

歳入

1.95B

純利益

529.4M

発行済株式数

140,866,112

浮動株比率 (%)

87.40%

機関投資家保有比率 (%)

38.45%

配当利回り

1.8 (2.54%)

PER

19.15

株価売上高倍率 (PSR)

5.19

1 株当たり利益 (EPS)

3.76

ベータ

0.29

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; ... Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. It offers pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Quetiapine products for antipsychotic; Trexan for rheumatoid arthritis and cancer; Easyhaler product portfolio for asthma and COPD; and Dexdor, Precedex, and Dexmedetomidine products for human use. The company also provides Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, it offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells drugs and products manufactured by other companies. Additionally, the company provides self-care products, including non-prescription medicines, cosmetics, dietary supplements, vitamins, and skincare products. It also offers its products online. The company has a licensing agreement with Tenax Therapeutics, Inc. to develop oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF); and Bayer for the development and commercialisation of darolutamide Nubeqa. Orion Oyj was founded in 1917 and is headquartered in Espo, Finland. 詳細を表示

セクター

業界

ウェブサイト

www.orionpharma.com

本社

Espo, Finland

設立

2026

Orion Corporation A is listed in the sector of the ロンドン証券取引所 with ticker 0M2N. The last closing price for Orion Corporation A was 33.03 €. Over the last year, Orion Corporation A shares have traded in a share price range of 33.025 € to 33.025 €.

Orion Corporation A currently has 140,866,112 shares in issue. The market capitalisation of Orion Corporation A is 4.65 € billion. Orion Corporation A has a price to earnings ratio (PE ratio) of 19.15.

表示するニュースはありません。

期間 †	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	DE
4	0	0	0	0	0	DE
12	0	0	0	0	0	DE
26	33.025	33.025	33.025	447	33.025	DE
52	33.025	33.025	33.025	571	33.025	DE
156	33.025	33.025	33.025	426	33.025	DE
260	33.025	33.025	33.025	341	33.025	DE